Frequency: Weekly (Goes into printing every Tuesday; On stands …
Launched on 21 December 2000, Chronicle Pharmabiz is the No. 1 Pharma news weekly in the South Asian markets; with a target readership that includes 100% coverage of top and middle management pharma professionals across the region.
Zealand Pharma’s NDA for glepaglutide gets US FDA complete …
2 天之前 · Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for its New Drug Application (NDA) for glepaglutide, a long-acting GLP-2 ...
US FDA approves Ionis Pharma’s Tryngolza to treat adults living …
2 天之前 · Ionis Pharmaceuticals, Inc, a biotechnology company that develops RNA-targeted therapeutics, announced that the US Food and Drug Administration (FDA) has approved Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare ...
News - Pharmabiz.com
5 天之前 · Pharmabiz.com - India's most comprehensive online pharma news service. It provides updates on Indian pharma industry, allied sectors like hospitals & diagnostic services,pharma tenders, pharma projects, pharma export & import, pharma laws & documents, pharma policies, pharma events, pharma company profiles, pharma studies, pharma marketing
Gerresheimer announces US FDA grants tentative approval for SQ ...
2024年12月17日 · Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetics industries, announces that the US Food and Drug Administration (FDA) granted SQ Innovation Tentative Approval for Lasix ONYU for the home treatment of fluid overload in congestive ...
Neurizon files IND application to US FDA seeking approval to …
5 天之前 · Neurizon Therapeutics Limited, a clinical-stage biotech company advancing treatments for neurodegenerative diseases, announced the filing of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for its lead candidate, NUZ-001. This milestone is a pivotal step in ...
AstraZeneca’s Imfinzi receives US FDA approval to treat patients …
2024年12月6日 · AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. The approval was granted by the Food and ...
Editorial - Pharmabiz.com
2024年11月6日 · Pharmabiz.com - India's most comprehensive online pharma news service. It provides updates on Indian pharma industry, allied sectors like hospitals & diagnostic services,pharma tenders, pharma projects, pharma export & import, pharma laws & documents, pharma policies, pharma events, pharma company profiles, pharma studies, pharma marketing
AstraZeneca & Merck announce OlympiA phase 3 trial of Lynparza ...
2024年12月13日 · AstraZeneca and Merck, known as MSD outside of the United States and Canada, announced long-term results from the OlympiA phase 3 trial which showed Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS) and ...
US FDA accepts and granted Priority Review status to …
2024年8月16日 · US FDA accepts and granted Priority Review status to AstraZeneca’s sBLA for Imfinzi to treat patients with limited-stage SCLC: Cambridge, UK Friday, August 16, 2024, 16:00 Hrs [IST]